IP fights, bio‑based consolidation and marketing scrutiny: Five forces reshaping global beauty in 2026

Table of Contents

1. Key Highlights:
2. Introduction
3. Intellectual property at the center: the Kolmar–Intercos sun‑care case and what it means
4. Cross‑industry partnerships become a strategic lever: CLEAR and Red Bull Racing
5. Botanical innovation and exosome science: Taiwanese orchid vesicles as a new ingredient frontier
6. Biotech consolidation: Solabia’s acquisition of Mibelle and the business case for bio‑based scale
7. Market maturity and growth normalization: Puig’s performance and the fragrance outlook
8. Color cosmetics under pressure: bankruptcies, acquisition activity and shifting consumer demand
9. Transparency disputes and consumer protection: the Supergoop! ‘100% mineral’ class action
10. Advertising policing: NAD’s mixed ruling on Revlon’s ColorSilk and the boundaries of efficacy language
11. Philanthropy as brand architecture: M·A·C’s VIVA GLAM surpasses $540 million raised
12. Strategic implications for the industry: what brands, suppliers and regulators should prioritize
13. FAQ

Key Highlights:

• Intellectual property preservation and employee mobility are driving high‑stakes litigation in sun care and beyond, as seen in Kolmar Korea’s win over Intercos and mounting consumer class actions over label claims.
• Biotech consolidation and botanical innovation are accelerating product pipelines and sustainability claims — Solabia’s acquisition of Mibelle and Taiwanese orchid exosome research illustrate complementary paths to growth.
• Brand strategies are fragmenting between experiential partnerships and philanthropic platforms while regulatory and self‑regulatory scrutiny tightens around advertising language and absolute ingredient claims.

Introduction

The beauty industry is navigating a moment of sharpening commercial and legal pressures while simultaneously investing in scientific differentiation and brand experience. Recent headlines collected across Asia‑Pacific, EMEA and North America illustrate competing priorities: protecting proprietary formulations, pursuing scale through M&A in bio‑based actives, reimagining brand reach with sports partnerships, and facing renewed scrutiny over marketing language from regulators, non‑profits and courts.

Taken together, these developments signal an industry balancing intensive innovation with greater external oversight. Corporates are doubling down on intellectual property protection and trackable science for ingredients; at the same time, consumer expectations around transparency and sustainability are turning marketing claims into potential legal flashpoints. Firms that manage this dual imperative — inventing defensible technology and communicating it precisely — will find an advantage. The stories below explain how that is already playing out and what brands, suppliers and formulators should be watching in the months ahead.

Intellectual property at the center: the Kolmar–Intercos sun‑care case and what it means

Kolmar Korea’s recent victory in a years‑long dispute with Intercos Korea highlights a recurring fault line: employee mobility versus the protection of trade secrets. According to the case record, a long‑standing Kolmar R&D employee moved to Intercos in 2018 and transferred core research materials, including proprietary sunscreen formulations and new product development data. A second former employee allegedly participated in the exfiltration. The litigation concluded with Kolmar prevailing, underlining the enforceability of trade secret protections in jurisdictions across APAC when supported by documentary evidence and forensic investigation.

Why the case matters beyond the parties involved

The cosmetics sector depends on formulation know‑how, minor compound tweaks and process improvements to yield meaningful competitive advantage. Unlike patentable molecular entities in pharmaceuticals, many beauty innovations are packaged as trade secrets and guarded through access controls, employee agreements and carefully defined development protocols. The Kolmar win signals three practical takeaways:

• Contracts and enforcement matter. Non‑disclosure agreements, clearly delineated IP ownership clauses and well‑documented chain‑of‑custody records strengthen legal remedies when proprietary information moves with personnel.
• Operational controls are as important as legal language. Digital access logs, segmented R&D environments and exit interview protocols can limit exfiltration and create the audit trail judges and regulators expect.
• Jurisdictional clarity is essential. Multinational supply chains and cross‑border employment complicate enforcement. Companies must understand where trade secret laws are robust and where supplemental protections — such as immediate injunctive relief — are feasible.

Real‑world parallels and lessons for in‑house counsel

Comparable disputes have surfaced in other technology‑adjacent sectors. In software and semiconductors, courts have increasingly recognized that employee transfers necessitate prophylactic safeguards to avoid misappropriation. Beauty companies can borrow tactics: deploy real‑time monitoring of repository access, implement differential access for confidential projects, and require departing employees to certify that no proprietary files were transferred.

A separate but related consideration is supplier risk management. When R&D partners or co‑packers hire former employees from competitors, clients should audit data hygiene and contractually demand confirmation that no third‑party IP was received. Audits and compliance clauses can be built into supplier agreements to reduce downstream legal exposure.

Cross‑industry partnerships become a strategic lever: CLEAR and Red Bull Racing

CLEAR’s collaboration with Red Bull Racing exemplifies how personal care brands are leveraging high‑performance sports platforms to reposition product benefit narratives. CLEAR, established in anti‑dandruff and scalp care, is applying the motorsport partner model to signal precision, endurance and performance under stress — attributes that translate to day‑to‑day consumer needs such as confidence during high‑pressure situations.

Why F1 and motorsports attract beauty brands

Formula One teams offer more than a logo on a jacket. They provide an association with engineering rigor, rapid iterative development and extreme performance testing. Brands seeking to move from lifestyle to performance positioning find motorsport appealing for three reasons:

• Credibility cues. Associations with teams imply functional efficacy without explicit clinical claims. Consumers draw inferences from brand alignment with elite performance.
• Co‑development potential. Access to high‑tech materials, aerodynamic testing minds and rapid prototyping cultures can inform R&D approaches for formulations meant to withstand heat, sweat and extended wear.
• Experiential marketing. Pit‑lane activations, integration into live events and digital storytelling create premium touchpoints that extend beyond conventional retail.

Precedents and variations

Elemis previously explored the racing channel with "pit‑stop" treatment concepts translated to retail, demonstrating a pathway from experiential spa services to consumer products. Partnerships can take many forms: research collaborations that test new ingredient stability under high temperature and vibration; limited‑edition co‑branded product launches; and athlete or team‑member endorsements that reflect lifestyle resilience more than lab performance.

Risks and practical considerations

Brand partnerships with sports teams must be calibrated to avoid overstating technical benefits. When affinity leads to implied performance claims, marketing language must tether to evidence. Cross‑industry collaborations also require careful IP negotiation: who owns co‑developed formulations or campaign creative? Agreements should specify ownership and usage rights upfront to avoid later disputes similar in nature to the IP litigation issues discussed earlier.

Botanical innovation and exosome science: Taiwanese orchid vesicles as a new ingredient frontier

Researchers in Taiwan isolated exosome‑like vesicles from the Phalaenopsis aphrodite orchid — a species popularly known as “Taiwanese Grandma” — and reported potential skin protection and brightening activity. The work marks the first time these nano‑scale biological packages have been isolated from this specific orchid for cosmetic application.

What exosome‑like vesicles bring to cosmetics

Exosomes are naturally occurring, membrane‑bound vesicles used by cells for intercellular communication. In cosmetics, exosome‑like vesicles from plants are proposed as carriers of proteins, lipids and small RNAs that can modulate biological pathways relevant to skin barrier function, pigmentation and antioxidative responses.

Advantages advertisers might claim include:

• Targeted delivery potential. Vesicles can theoretically enhance uptake of bioactive payloads across the stratum corneum, improving efficacy at lower doses.
• Novel selling points. Plant‑derived exosomes offer differentiation in a crowded natural‑ingredient market.
• Compatibility with bio‑based narratives. Consumers seeking botanically derived alternatives view such technologies as more natural than synthetic delivery systems.

Caveats and evidence requirements

Scientific enthusiasm must be matched by rigorous, reproducible data. Key questions that brands and formulators should address before commercializing exosome‑based ingredients:

• Characterization: Are the vesicles fully characterized (size, surface markers, cargo) and reproducibly isolated at scale?
• Mechanism and efficacy: Does cargo reach target cells in vivo, and does it elicit measurable changes in skin physiology that correlate with consumer‑relevant outcomes?
• Safety and regulatory: How do regulators classify plant‑derived vesicles? Is there a precedent for such biologics in cosmetic dossiers across major markets?

The Taiwanese study involved collaboration among industry and academic partners, which strengthens translational potential. Scaling from lab isolation to consistent, GMP‑grade ingredient production remains a major hurdle; however, if safety and efficacy studies validate the initial promise, exosome vesicles could seed a new class of high‑end actives.

Comparative examples in ingredient innovation

The industry has previously moved from niche botanical discoveries to mainstream actives after a period of validation. Consider the trajectory of bakuchiol: initially a niche, plant‑derived alternative to retinol, bakuchiol gained scientific and commercial traction once clinical evidence supported comparable efficacy with fewer irritations. A similar path could be possible for plant exosomes — but only with transparent clinical data and robust manufacturing controls.

Biotech consolidation: Solabia’s acquisition of Mibelle and the business case for bio‑based scale

Solabia’s announced acquisition of Swiss ingredients specialist Mibelle Biochemistry reflects a larger pattern: active ingredient companies consolidating to accelerate capabilities in natural and bio‑based actives. Solabia, a French biotech focused on health and beauty, cited complementary technologies and product strengths as the rationale for the deal.

Why scale matters for bio‑based innovation

The market for bio‑based actives is fragmenting into many specialized firms. Consolidation achieves multiple strategic goals:

• Broader R&D platforms. Combining labs, technology stacks and talent pools enables more integrated pipelines from discovery to commercialization.
• Cost efficiencies. Shared manufacturing, regulatory and marketing resources reduce unit costs and speed time to market.
• Portfolio diversification. Buyers can offer a range of actives that address multiple skin concerns, appealing to formulators seeking multi‑ingredient solutions.

Commercial drivers behind Solabia’s move

Mibelle brings recognized proprietary actives and formulations expertise. Solabia gains immediate access to those technologies, strengthening its natural active roster while inheriting existing customer relationships. This accelerates growth compared with organic R&D, where time‑to‑market can be months to years longer.

Implications for brands and formulators

Consolidation reduces fragmentation for procurement teams and may simplify supply chain management. However, it can also reduce the diversity of niche suppliers available to indie brands. Buyers should assess potential post‑acquisition impacts on pricing, lead times and innovation cadence. For ingredient businesses, the tradeoff becomes balancing independence with the capital and market access that an acquirer brings.

Regulatory and sustainability angles

Large ingredient groups are equally compelled to meet rising sustainability reporting expectations. Acquisitions often aim to combine not just science but also certifications, traceability mechanisms and green chemistry processes. Companies seeking to lead in bio‑based innovation must demonstrate cradle‑to‑gate sustainability metrics, which become more credible when larger firms invest in standardized auditing and supply‑chain transparency.

Market maturity and growth normalization: Puig’s performance and the fragrance outlook

Spanish luxury house Puig announced record revenue performance — crossing €5 billion — while signaling expectations that the fragrance market would “normalize” after a period of rapid growth. Puig’s trajectory illustrates how even high‑growth segments can face cyclical correction.

What normalization means for brands and investors

Rapid category expansion often attracts new entrants, premiumization strategies and elevated marketing spend. Normalization signals a return to longer‑term, sustainable growth rates aligned with consumer purchasing power and channel evolution. For fragrance, this might mean slower expansion in premium gifting occasions, greater emphasis on sampling and discovery, and pressure to demonstrate repeat purchase drivers like longevity and formulation distinctiveness.

Strategic responses available to fragrance companies

• Differentiation through formulation and storytelling. When top‑line growth slows, maintaining margin often depends on unique olfactory assets, pedigree ingredients and co‑creative narratives tied to perfumers or provenance.
• Channel optimization. Direct‑to‑consumer sampling strategies and subscription models can stabilize demand by increasing trial and incremental repurchase.
• Portfolio rationalization. Firms may prioritize brands and SKUs that demonstrate loyal customer bases or higher gross margins.

Puig’s results also underscore the importance of multi‑category balance. Houses that couple fragrance with skincare, color or accessories can offset softness in one division with strength in another, a useful hedge when consumer preferences shift.

Color cosmetics under pressure: bankruptcies, acquisition activity and shifting consumer demand

Early 2026 brought high‑profile turbulence in color cosmetics. Iconic indie Pat McGrath Labs filed for Chapter 11, while legacy UK brand Barry M pursued a buyer amid rising manufacturing costs and challenging margins. These events expose structural pressures in color cosmetics that extend beyond brand identity.

Structural factors driving stress in color cosmetics

• Trend volatility. Color preferences and finishes (matte, glossy, dewy) shift rapidly. Viral moments on social platforms can accelerate demand one month and render palettes unsellable the next.
• Production cost inflation. Pigment pricing, specialized dispersions and colorant supply chains are sensitive to feedstock and logistics inflation, compressing margins for mid‑size players.
• Distribution challenges. Retail consolidation and the dominance of fast delivery models increase the cost of shelf placement and promotional activity. Brick‑and‑mortar exposure can be a liability when footfall declines.

Why some brands fail and others adapt

Success in color requires rigorous inventory forecasting, flexible manufacturing and an omnichannel marketing strategy that preserves margin. Brands that scale rapidly often face supply chain friction that outpaces capital. Smaller brands face difficulty absorbing promotional costs while investing in product development.

Opportunities for reinvention

• Niche specialization. Narrowing focus to specific consumer segments (professional makeup artists, eco‑conscious consumers, or inclusive shade ranges) can create defensible niches.
• Vertical integration. In‑house pigment blending or closer partnerships with mills can reduce dependency and manage costs.
• Digital‑first creativity. Leveraging AR try‑on and influencer seeding can create demand without excessive retail markdowning.

Industry consolidation often follows these periods, as buyers seek to acquire distressed but recognized brands for intellectual property, SKUs with loyal customers, or established distribution relationships.

Transparency disputes and consumer protection: the Supergoop! ‘100% mineral’ class action

A class action filed in California targets Supergoop! products marketed as “100% Mineral” or “Mineral,” alleging that labeling created a misleading impression because formulas include non‑mineral or synthetically processed ingredients. The complaint highlights a broader trend: consumer litigation focused on absolute or categorical claims that imply purity, naturalness or total composition.

Legal mechanics and consumer expectations

At the heart of such suits is the idea that marketing language creates an overall impression, not just a literal ingredient list. Plaintiffs argue that terms like “100% mineral” convey that the entire formula is mineral‑based and therefore natural or safer, even when the active UV filters are mineral while formulants or stabilizers are synthetic.

Consequences for labeling and product development

• Precision in language. Brands must calibrate claims to reflect what is actually true about the product as a whole. Saying “Mineral SPF Actives” rather than “100% Mineral” places the emphasis accurately on the active component.
• Ingredient transparency. Detailed on‑pack or online ingredient breakdowns help manage consumer expectations. Explainers that define “mineral” versus “mineral‑based” reduce interpretive gaps.
• Marketing risk assessment. Legal review of claims should evaluate not only literal accuracy but also consumer inference risk. Third‑party organizations such as Truth in Advertising (TINA.org) are vigilant and may catalyze litigation through reports.

Wider implications for natural and “clean” positioning

The lawsuit against Supergoop! is part of a wave of cases challenging absolute natural claims across categories. The litigation climate encourages brands to document substantiation and consider consumer perception testing as part of pre‑launch due diligence. For smaller companies, defensive strategies include conservative claims, transparent educational content and readiness to modify messaging if regulators or self‑regulatory bodies raise concerns.

Global considerations

Regulatory definitions of “natural,” “organic” and similar descriptors vary widely between jurisdictions. A claim that survives scrutiny in one market may be contested elsewhere. Global brands must craft market‑specific labeling approaches and coordinate claims review across legal teams.

Advertising policing: NAD’s mixed ruling on Revlon’s ColorSilk and the boundaries of efficacy language

Following a competitor challenge from Henkel, the National Advertising Division (NAD) reviewed Revlon’s claims for ColorSilk hair color featuring a “Bond Repair Complex.” The NAD concluded that some claims were supported while others should be modified or discontinued. The decision underscores the precision required for benefit language tied to underlying evidence.

How NAD decisions shape industry practice

The NAD is an influential self‑regulatory body in the U.S. whose reviews often lead to voluntary compliance or changes in advertising prior to escalations to federal regulators or litigation. NAD’s mixed decisions deliver practical guidance:

• Substantiate specific claims. General statements that a product “repairs bonds” require defined testing that measures the specific structural metric referenced.
• Avoid overreach. Language that implies clinical parity with professional treatments requires stronger substantiation.
• Update packaging and digital content across channels. NAD decisions typically demand modifications wherever the claim appears, from product labels to retailer listings and paid media.

Practical steps for marketers and R&D teams

Integrate claim validation into the product development timeline. Rather than post‑hoc legal reviews, effective teams include evidence generation (bench tests, consumer panels, clinical trials) before claims are finalized. Maintain a cross‑functional repository that links each marketing claim to the supporting study, methodology and internal sign‑off to expedite responses if challenged.

Competitive dynamics

Competitor challenges, like Henkel’s, reflect the reality that advertising is a battleground for market share. Brands must anticipate that contentious claims invite scrutiny. The best mitigant is conservative, actionable language anchored in reproducible evidence.

Philanthropy as brand architecture: M·A·C’s VIVA GLAM surpasses $540 million raised

M·A·C Cosmetics’ VIVA GLAM program has raised over $540 million since 1994 and impacted more than 60 million lives, according to the brand’s 2025 Impact Report. The program’s fundraising continued, with $4.5 million donated to 64 nonprofit partners in the latest reporting year, focusing on sexual, racial, gender and environmental equality.

Why long‑running philanthropic platforms matter for beauty brands

Almost three decades of sustained giving illustrate how philanthropy can serve as more than occasional corporate social responsibility (CSR): it becomes a brand institution that shapes corporate identity, consumer loyalty and stakeholder relations. VIVA GLAM’s longevity generates several strategic advantages:

• Trust and authenticity. Consistent funding over decades builds credibility that short, high‑profile campaigns cannot replicate.
• Consumer alignment. Customers motivated by social impact may prefer brands demonstrating measurable, long‑term commitments.
• Employee engagement. Purpose‑driven programs help attract talent, particularly among workers seeking mission‑aligned employers.

Scaling impact while managing expectations

Sustained philanthropic platforms must periodically recalibrate to remain relevant. M·A·C sharpened its focus on partnerships that advance equality across multiple dimensions, reflecting social priorities that have evolved since the 1990s. The challenge for brands is to maintain measurable outcomes and transparent reporting so consumers and partners can assess impact.

Integration with product strategy

VIVA GLAM links product sales directly to giving: proceeds from specific SKUs fund the program. This model has advantages: it creates a clear consumer action-to-impact link and allows brands to track revenue‑to‑donation ratios. However, it also invites scrutiny over administrative costs, selection of partner organizations, and the proportionality of donations relative to product margins.

Philanthropy and brand risk

Public philanthropic programs are subject to reputational risk if brand actions elsewhere appear inconsistent with the stated mission. A program that supports LGBTQ+ charities, for instance, may be judged against the brand’s employment or sourcing practices. Consistency and transparent governance are necessary to shield a philanthropic platform from being perceived as performative.

Strategic implications for the industry: what brands, suppliers and regulators should prioritize

Taken together, these regional stories outline a strategic agenda for industry stakeholders.

1. Protect core know‑how while enabling talent mobility. Companies must craft employment agreements and data governance that protect trade secrets without stifling legitimate career movement. Practical measures include segmented repositories, clear IP ownership language, regular audits, and rapid legal escalation protocols when breaches occur.
2. Invest in evidence that supports claims before launch. The NAD’s scrutiny and consumer class actions demonstrate that the cost of overstatement can be immediate and material. Brands should embed validation — lab analyses, clinical studies, consumer perception tests — into launch timelines and maintain a living dossier linking claims to evidence.
3. Build scalable sustainability and bio‑based strategies. M&A, as in Solabia’s acquisition of Mibelle, will remain a route to build robust portfolios of bio‑based actives. When acquiring, prioritize manufacturing traceability, validated sustainability metrics and integration roadmaps that protect existing customer commitments.
4. Anticipate marketing inferences, not only literal accuracy. Legal teams must evaluate how consumers infer brand statements. Simple shifts in phrasing — from categorical labels to precise descriptors — reduce litigation risk. Labels should reflect the entirety of the product, not solely the headline ingredient.
5. Use partnerships strategically, not opportunistically. Experiential alliances such as CLEAR’s collaboration with Red Bull Racing can amplify positioning, but the partnership must be consistent with product benefits and supported by operational agreements clarifying IP ownership, joint R&D rights and co‑marketing governance.
6. Maintain philanthropic integrity. Long‑running CSR platforms deliver brand differentiation when they demonstrate transparency, clear metrics and alignment between actions and stated values.

These priorities are not mutually exclusive. The most resilient companies will integrate them: defending IP, validating claims, scaling bio‑based innovation and aligning brand actions with social commitments.

FAQ

Q: How can beauty companies reduce the risk of trade secret theft when employees move to competitors?
A: Combine contract remedies (NDAs, IP assignment clauses) with technical controls (role‑based access, audit trails, restricted file downloads) and operational processes (exit checklists, immediate access revocations). Conduct periodic compliance training and have a prepared legal response plan for suspected breaches.

Q: Are plant‑derived exosome‑like vesicles ready for commercial cosmetic use?
A: Scientific progress is promising, but commercial readiness depends on reproducible isolation techniques, safety data, robust efficacy endpoints measured in well‑designed studies, and a clear regulatory classification. Companies should complete scale‑up validation and transparent clinical testing before large‑scale marketing.

Q: What should marketers do to avoid claims litigation like the “100% mineral” case?
A: Use precise, unambiguous language and ensure that marketing claims reflect the product as a whole. Pre‑launch consumer perception testing, legal review, and publicly available ingredient breakdowns reduce the risk that a claim will create misleading impressions.

Q: How will ingredient supplier consolidation affect formulators and brands?
A: Consolidation may simplify procurement and offer more integrated R&D services, but could reduce the number of specialized suppliers. Brands should diversify supply sources, negotiate favorable contract terms, and assess post‑acquisition continuity plans for critical actives.

Q: What evidence level do advertising review bodies like NAD expect?
A: NAD looks for substantiation that directly supports the claim’s content and consumer interpretation. This may include bench tests, clinical trials, or third‑party validations depending on the claim’s specificity and the product category. The more specific or technical the benefit, the stronger and more direct the evidence required.

Q: Can partnerships with sports teams translate into demonstrable product performance?
A: Partnerships provide credibility and experiential marketing assets. Demonstrating product performance still requires specific testing (e.g., sweat, humidity, heat stability). When a partnership implies performance benefits, brands should be prepared to substantiate those claims with relevant evidence.

Q: How should brands balance philanthropic commitments and commercial goals?
A: Integrate philanthropy into core brand architecture with measurable goals, transparent reporting and governance that aligns with corporate policies and employee practices. Ensure partner selection and donation mechanisms are auditable and that philanthropic claims are substantiated with impact data.

Q: What regulatory differences should global brands consider when making “natural” or “mineral” claims?
A: Definitions and enforcement vary. Some regions have stricter regulatory definitions for terms like “organic.” A claim acceptable in one jurisdiction may be actionable in another. Maintain a market‑by‑market claims map, coordinate legal review across regions, and consider conservative global language with localized clarifications where necessary.

Q: If a brand’s marketing claim is challenged by a competitor, what steps should it take?
A: Immediately compile the substantiating dossier linked to the claim, consult legal counsel specializing in advertising and consumer protection law, and engage with the challenger through established self‑regulatory channels (e.g., NAD) to resolve the dispute where possible. Prepare to modify or withdraw the challenged claim if independent review finds it unsupported.

Q: What should investors watch for in beauty companies given these trends?
A: Investors should evaluate IP protection strategies, pipeline integrity for novel actives, litigation exposure from marketing claims, M&A rationales for acquisitions in bio‑based spaces, and the authenticity and sustainability of philanthropic programs. Companies that demonstrate disciplined evidence generation, supply‑chain resilience and transparent governance are positioned more favorably.